Medical Developments share price halted amid 'significant near-term opportunities'

The company seeks to raise additional capital.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Medical Developments shares are on ice today 
  • The company seeks to raise $30 million to fund growth initiatives 
  • The Medical Developments share price is down more than 42% this year to date 

The Medical Developments International Ltd (ASX: MVP) share price is on ice today following a company requested trading halt.

The ASX granted the trading pause before market open. Prior to being put into the trading halt, the last bid for the Medical Developments share price was $2.40 apiece.

Woman holding out her hand, symbolising a trading halt.

Image source: Getty Images

What was announced?

Medical Developments advised that it will complete a fully underwritten capital raising of $30 million.

This will be comprised of a $15 million placement and a $15 million pro rata accelerated non-renounceable entitlement offer.

It hopes to achieve a cash balance of $49 million post offer to fund three core areas. Per the announcement:

Post transaction MVP's cash balance will be A$49m which will fund:

– continuing execution of the Company's direct sales strategy in the large European
market

– expansion of the Australian business into the emergency sector and further growth in
the ambulance sector

– further investment in business capability to enable global growth

The 1 for 9.5 pro-rata accelerated non-renounceable entitlement offer seeks to raise $15 million. It comes with 1 attaching option to acquire 1 fully paid ordinary share for every 2.5 new shares
issued.

Whereas the placement is targeted towards sophisticated investors with 1 option for every 2.5 new shares issued.

Speaking on the announcement, chairman Gordon Naylor said the company was "pleased with [its] strong revenue growth in FY22and expect this to continue into FY23".

"With a strong funding position following the capital raising, we look forward to investing to continue to deliver on our growth strategy."

The Medical Developments share price is down more than 42% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »